Hong I. Wan, Ph.D.

Dr. Wan currently serves as President & Chief Executive Officer at Tallac Therapeutics. She previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Prior to that, Dr. Wan held positions as Director, Translational and Molecular Medicine at Pfizer and Director, Clinical Translational Medicine at Wyeth. Before joining Wyeth, Dr. Wan was Project Lead and Senior Scientist at Renovis.

Jaume Pons

Dr. Pons currently serves as the President and Chief Executive Officer of ALX Oncology. He previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron.

Stephanie White

Stephanie joined the Lightstone Ventures and Advanced Technology Ventures finance team in 2018.  Stephanie also serves as the Controller at Morgenthaler Ventures, MPE Partners, and Canvas Ventures. She started her career at PricewaterhouseCoopers where she focused on multi-national corporate tax provisions as well as corporate, partnership, and high net worth individual tax planning and compliance.

Travis Boettner

Travis joined the Lightstone Ventures and Advanced Technology Ventures finance team in 2018. Travis is responsible for all aspects of accounting, tax, reporting, and compliance for LSV and ATV. Travis also serves as the Chief Financial Officer and Chief Compliance Officer at Morgenthaler Ventures, MPE Partners, and Canvas Ventures. Travis began his career in PwC’s San Jose office where he spent five years in their Private Company Services group.

Susan Molineaux

Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Proteolix was acquired by Onyx Pharmaceuticals in November 2009. Prior to joining Proteolix, Dr. Molineaux was Vice President of Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President of Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the immunology group at Merck, in Rahway, NJ.

Hanson S. Gifford, III

Hanson is a Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013.

Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV. Since its inception in 1998, Hanson has led The Foundry in all of its activities. These include the invention, identification and development of new technologies, the formation, financing, and staffing of over twenty new companies, and ongoing support of these new ventures as a board member. Success stories include Evalve (acquired by Abbott), Concentric (acquired by Stryker), Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), and several companies started by ForSight Labs, an Ophthalmology-focused incubator started by The Foundry and Eugene de Juan, MD.

Prior to The Foundry, Hanson was Vice President of Research and Development at Heartport, Inc., which had a successful IPO in 1996. From 1993-1998, he built and led a 62-person team at Heartport developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. In 1992-1993, Hanson co-founded and served as Managing Director of Bavaria Medizin Technologie, GmbH in Oberpfaffenhofen, Germany. In 1991, Hanson co-founded and served as President of Cardiovascular Therapeutic Technologies, Inc. which was acquired by Eli Lilly. From 1985-1990, Hanson worked at Devices for Vascular Intervention (DVI), in various engineering, clinical research and marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics.

Hanson is a co-inventor on over 340 issued US patents. Hanson is a Director of FIRE1, Tangible Science, and the latest Foundry companies.

Mark Deem

Mark is a Venture Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013.

Mark is currently a Managing Partner at the Foundry, LLC. The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over a dozen medical device companies. Success stories include Ardian (acquired by Medtronic), eValve (acquired by Abbott), and Concentric (acquired by Stryker). Mark joined The Foundry at its inception in 1998. In addition to spearheading the research and invention process on new clinical opportunities, Mark leads the early stage effort in The Foundry’s new companies until the company’s CEO and Senior Staff is hired.

Prior to joining The Foundry, Mark served in a founding role as consulting Director of Research and Development for Ventrica, Inc. Previously, Mark was a senior member of the Research & Development team at Medtronic Micro Interventional Systems. Mark joined MIS as one of the initial members of the company’s engineering team and remained there through the acquisition by Medtronic.

Previously, Mark held engineering positions with Devices for Vascular Engineering, Cordis Corporation and the USCI Division of C.R. Bard.

Mark has spent over twenty years in the design, testing and manufacture of medical devices. He is a co-inventor on over 230 issued and pending U.S. patents.

Mark serves as Chairman of the Board for FIRE1, Foundry Therapeutics 1, and is a Director for Half Moon Medical.

Stacy Enxing Seng

Stacy is a Venture Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. She joined the LSV team in March 2016.

Since 2013, Stacy has also focused her work on engaging as a Professional Director, serving as an Independent Director and Committee Member for both public and venture-backed private companies across the healthcare ecosystem.  Stacy currently serves as a non-executive Independent Director and member of the Compensation and Management Committee for Hill-Rom Holdings, Inc. (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc. (NASDAQ: LIVN).  Stacy also serves as Chairwoman of the Board for CALA Health, an Independent Director for PreCARDIA, as well as a Director for the Fogarty Institute, a non-profit educational innovator.  Past Director appointments include Claret Inc, (exited to Boston Scientific), Spirox, (exited to Entellus/Abbott) FIRE 1, (Covidien/Medtronic Investment), CVI (exited to Covidien/Medtronic) and Solace Therapeutics.

An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture.

Prior to Independent Director work, Stacy served as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career, Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement.

Stacy’s earlier work in medtech included sales and marketing management roles with SCIMED/Boston Scientific and sales and product management roles with American Hospital Supply/Baxter.

Hank Plain

Hank Plain is a General Partner of Lightstone Ventures. He also serves as a General Partner at Morgenthaler Ventures, which he joined in 2007 after more than 25 years in the pharma and medical device industry.

Mr. Plain began his career in 1980 with Eli Lilly. He left Lilly to become CEO of Perclose, where he led the company through a successful IPO and acquisition by Abbott Laboratories in 1999. Prior to becoming a venture capitalist, he co-founded eight medical device companies along with the team at The Foundry medical device incubator.

Mr. Plain serves on the boards of Earlens, Nuvaira, Moximed and Setpoint. He previously served on the boards of nine companies that were acquired – Claret Medical, Miramar Labs, Twelve Medical, Ardian, Access Closure, Acclarent, Cabochon, EPI and TransVascular.

Mr. Plain is Chairman of the Board of Trustees for the Naval Postgraduate School Foundation in Monterey, CA and the Future Citizens Foundation/First Tee of Monterey County.

Chris Christoffersen, Ph.D.

Chris was a Founding Partner of Lightstone Ventures and is currently a Special Partner. He focuses on biopharmaceutical investments out of the firm’s Boulder, CO, office. Chris joined Morgenthaler in 2001 and serves as a General Partner. His signature deals include Avidia (acquired by Amgen in 2006), Threshold (NASDAQ: THLD), Morphotek (acquired by Easai in 2007), FoldRx (acquired by Pfizer in 2010), and Nimbus Therapeutics/Apollo (partially acquired by Gilead in 2015). He serves on the boards of Adastra Pharmaceuticals, and previously on Nimbus. Chris brings to Lightstone more than 20 years of operations experience, having served as CEO and President of Ribozyme Pharmaceuticals (a/k/a Sirna Therapeutics; acquired by Merck for $1.2B), Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.

Chris is a recognized thought leader in the field of biotechnology. He received an honorary Doctor of Law degree from Cornell College in 1983, the Outstanding Research of Year Award from the International Society of Quantum Biology in 1981, the W. E. Upjohn Award for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association.